Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06027749 · ClinicalTrials.gov registry record · NA
Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.
A NA study of Epilepsy and Seizures, sponsored by Epitel.
- Recruiting
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 2
- Study locations
NCT06027749: Recruiting NA study of Epilepsy and Seizures, sponsored by Epitel.
NCT06027749 is a NA study of Epilepsy and Seizures that is actively recruiting participants, run by Epitel. The registered enrollment target is 65 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06027749, a NA study of Epilepsy and Seizures, is actively recruiting participants, sponsored by Epitel.
- RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: • Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? • Do treating clinicians find clinical value in extended fourteen (14) - twenty-eight (28) days of EEG? Participants will wear a portable EEG device (REMI) for fourteen (14) to twenty-eight (28) days in their home/community setting.
Interventions
- DEVICE Epitel's™ Remote EEG Monitoring System's (REMI™)
Study Locations (2)
Florida
- University of South Florida - Tampa
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2023-10-13 |
| Est. Completion | 2025-06-01 |
| Phase | NA |
What NCT06027749 shows while recruiting
NCT06027749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Epitel's™ Remote EEG Monitoring System's (REMI™) is the first listed.
NCT06027749 reports a single indexed study location in Florida, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06027749 about?
NCT06027749 is a clinical study titled "Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.". The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questi...
What is the current status of trial NCT06027749?
This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2023-10-13. Estimated completion is 2025-06-01.
What conditions does trial NCT06027749 study?
This clinical trial studies the following conditions: Epilepsy, Seizures.
What interventions are being tested in trial NCT06027749?
The interventions under investigation include: Epitel's™ Remote EEG Monitoring System's (REMI™) (DEVICE).
Who is sponsoring clinical trial NCT06027749?
This trial is sponsored by Epitel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06027749 being conducted?
This trial has 2 study locations across Florida, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06027749's enrollment target sits among peer trials
65 75th of 160 higher than 86 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SeizEAR Safety Study
RECRUITING · NA
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
-
Subcortical Arousal in Perceptual Awareness
RECRUITING · NA
-
Prediction of Anxiety and Memory State
RECRUITING · NA
-
Implementation and Cost Evaluation of Project UPLIFT
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI